The 6th Microbiome Movement – Drug Development Summit is THE must-attend conference for microbiome drug developers.
It is the perfect opportunity for the industry to take a collaborative approach to close the clinical gap, discover the next generation of microbiome-based therapeutics, and establish new partnerships to accelerate their research.
Jean De Gunzburg, CSO, will deliver a presentation entitled ‘Protecting and preserving the intestinal microbiota from antibiotic-induced dysbiosis with DAV132, a novel colon-targeted adsorbent: an effective and safe solution for cancer patients’ at the upcoming virtual Microbiome Movement Drug Development Summit, on Wednesday, June 30 at 18:40 CEST (12.40pm EDT).
The presentation will highlight:
• DAV132, a first-in-class chemical product that sequesters and inactivates antibiotics circulating in the colon is able to preserve patients’ intestinal microbiota without impacting antibiotics’ plasma pharmacokinetics and efficacy, in a Phase 2 clinical study,
• The understanding of DAV132 mode of action in humans is reinforced by a series of clinical studies conducted in healthy subjects and including microbiota analyses,
• Additional work showing the importance of protecting the microbiota of cancer patients treated with immune checkpoint inhibitors will also be presented.
The event programme is available here on the event website.